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ABSTRACT
Introduction. Multiple Sclerosis (MS) is a chronic, demyelinating disease of the central nervous system which affects mostly 
young people. Because it leads to disability and cognitive impairment, it is crucial to recognise MS at an early stage. 
State of the art. Magnetic resonance imaging is the golden standard in MS diagnosis. However, it is not an infallible diagnostic 
tool, especially at the stage of clinically isolated syndrome. The incorporation of oligoclonal bands in the diagnostic process of 
MS is a step towards the extension of diagnostic methods. Recently, a lot of research has been carried out on potential biomar-
kers in blood serum and cerebrospinal fluid that may be useful in the diagnosis of MS.
Clinical implications. This article summarises current knowledge on the use of new prognostic factors such as neurofilament 
light chain, chitinase 3-like 1 and 2, heat shock proteins, and tubulins in MS. 
Future directions. Despite numerous studies on the use of biomarkers in the diagnosis of MS, more extensive research is 
needed to determine the clinical usefulness of these molecules and to develop diagnostic tests applicable in everyday practice. 
This in turn may result in earlier MS detection, faster implementation of treatment, and better therapeutic effects.
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Introduction
Multiple Sclerosis (MS) is a chronic, inflammatory, de-
myelinating disease of the central nervous system (CNS) with 
a wide spectrum of clinical and imaging changes [1, 2]. The 
first episode of neurological symptoms with the features of 
inflammatory demyelination is referred to as clinically isolated 
syndrome (CIS) [3]. This develops acutely or subacutely, lasts 
at least 24 hours, and runs a course similar to that of a typical 
MS relapse but in a patient not yet diagnosed with MS [3, 4]. 
Research has shown that up to 60–70% of patients with a first 
clinical episode do not meet the criteria for MS. However, up 
to 85% of these patients will develop full-blown MS in the 
future [5, 6]. 
According to the new, revised McDonald criteria from 
2017, magnetic resonance imaging (MRI) is the golden stan-
dard in MS diagnosis [7]. The risk of conversion from CIS to 
clinically definite MS (CDMS) in patients with characteristic 
lesions in MRI is up to 60–80 %, while in patients without 
abnormalities specific for MS this risk is 20% at most [3, 8, 9]. 
Unfortunately, MRI is not effective enough to detect all active 
demyelinating changes in the CNS. MS affects approximately 
2.3 million people, mostly between the ages of 20 and 40, 
leading to their disability and cognitive impairment. This 
makes it a significant problem for society as a whole [10]. 
Currently available treatment can delay the progression of 
MS only if it is used at the beginning of the disease. This is 
why early diagnosis of MS has become a burning clinical 
challenge. It is essential to properly recognise it from the 
very earliest stages of the disease. The above-mentioned 
McDonald criteria put emphasis on the early detection of the 
CIS. In addition to magnetic resonance, oligoclonal bands 
(OCBs) play a key role in the diagnostic process. Moreover, 
recent promising studies have been carried out to determine 
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the presence and concentration of new biochemical indica-
tors in the cerebrospinal fluid (CSF) and blood serum that 
may be useful in MS diagnosis. 
State of the art
Oligoclonal bands as predictive factors of MS
OCBs are mostly immunoglobulins G (IgG), which are 
produced intrathecally by stimulated clones of B lymphocytes 
and plasma cells. It is believed that the final maturation of B 
lymphocytes, and their affinity for a closer unknown antigen, 
occurs in the peritoneum and meninges (Fig. 1) [11, 12]. CSF 
and the serum are tested by isoelectric focusing (IEF) gel 
electrophoresis for the presence of so-called bands. There are 
six types of OCBs: types 2 and 3 indicate intrathecal synthesis; 
the other four are negative for MS (Tab. 1) [13–15].
The importance of oligoclonal bands in the diagnosis of 
MS has been the subject of several studies. A large study con-
ducted by 33 centres included 1,047 patients with CIS observed 
for a minimum of two years. With a median follow-up of 
4.31 years, 623 patients with CIS converted to MS. Oligoclonal 
bands were detected in 95% of patients [6].
Another multicentre retrospective study, conducted by 
German-Austrian scientists, included 406 patients. The diag-
nostic criteria for MS were met by 11% of patients (44 people), 
and the remaining 89% (362 people) were diagnosed with 
CIS. OCBs were positive in 86% of patients with CIS; 74% 
of these patients developed MS. OCBs were not detected in 
14% of patients; 44% of these patients converted to MS. The 
median conversion time for CIS patients with positive OCBs 
was 25 months, compared to 47 months in patients with nega-
tive OCBs [16].
Another study included 120 patients with CIS. Conversion 
to MS was observed in 42% of cases, and 58% of patients was 
defined as stable CIS. Positive OCBs were detected in 61% of 
patients with CIS at the beginning of the study. During follow-
up, 55% of patients with positive OCBs converted to MS, and 
21% of patients with negative OCBs developed MS. The median 
time needed for conversion was similar in both groups [17]. 
These two studies show that people with CIS and positive test 
results for OCBs are twice as likely to develop MS than people 
with negative OCBs. However, in the German-Austrian study, 
the conversion time to MS was almost twice as long in patients 
with negative OCBs than it was in patients with positive OCBs.
Recent research has also focused on the value of intrathecal 
immunoglobulin M (IgM) synthesis in the diagnosis of MS. 
A study involving 126 patients with CIS showed that IgM levels 
have a higher reliability index for the conversion of patients 
with CIS to CDMS compared to IgG [18].
Generally, oligoclonal bands are a strong independent 
predictor of the risk of conversion in patients with CIS to 
CDMS: this has been proven by numerous studies. Based 
on this, an oligoclonal bands test was included in the latest 
(2017) McDonald criteria, not only as a criterion of MS but 
also as a predictor for a second relapse occurrence in patients 
diagnosed with CIS [7]. Moreover, OCBs are not specific indi-
cators for MS, because an increased level of OCBs can occur 
in other infectious and inflammatory diseases of the central 
nervous system [19, 20]. 
New potential biochemical indicators of MS
Neurofilament light chain
Neurofilaments (NFs) are larger molecules of the neuronal 
cytoskeleton. They are divided into three subgroups: light, 
medium, and heavy [21]. Neurofilaments are neuron-specific 
proteins that are released during neuronal damage. This 
process is the main element of pathology in MS. Therefore 
it may result in the occurrence of neurofilament light chain 
(NFL) in the cerebrospinal fluid and then in the blood serum 
[22–24]. It is believed that axonal damage occurs in the early 
stages of MS [25, 26].
Table 1. Types of OCBs depending on their pattern in IEF and occurrence 
in body fluids [13]
IEF pattern Occurrence in body fluids
1 No OCBs in CSF and serum
2 CSF-restricted IgG OCBs
3 CSF-restricted OCBs and additional identical bands in 
CSF and serum (combination of patterns 2 and 4)
4 Identical OCBs in CSF and serum (‘mirror pattern’)
5 Monoclonal bands in CSF and serum
6 Presence of a single band limited to CSF
OCBs — oligoclonal bands; IEF — isoelectric focusing; CSF — cerebrospinal fluid; IgG — immuno-
globulin G
Figure 1. Intrathecal synthesis of immunoglobulins G forming 
-
ninges, where they go through maturation process and acquire 
lymphocytes after contact with antigen. Stimulated B lymphocytes 
start producing immunoglobulins G, which form oligoclonal bands; 
IgG — immunoglobulin G; OCB — oligoclonal band
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The role of the neurofilament light chain as a diagnostic 
factor in MS has been the subject of much research. A prospec-
tive longitudinal cohort study included 41 patients with CIS or 
relapsing-remitting multiple sclerosis (RRMS) and 22 healthy 
patients. Patients’ cerebrospinal fluid was analysed for many 
biomarkers, including neurofilament light chain. In addition, 
during the two-year follow-up, the activity of the disease was 
evaluated by assessing relapses, worsening of disability, or 
magnetic resonance imaging activity. The study showed that 
NFL turned out to be the best predictor of MS development 
at the baseline. Within two years of follow-up, based on the 
NFL level, 93% of patients who showed signs of disease activity, 
as well as 67% of patients who did not, were correctly classi-
fied. The overall percentage of correct classifications was 85% 
(33/39 patients) [27].
Another study included 85 RRMS patients whose serum 
was collected and tested for NFL and its potential role as 
a predictor of disease activity. Patients were followed for two 
years. They did not receive disease-modifying treatment for 
the first six months, then for the next 18 months they received 
interferon-beta 1a (IFNB-1a). Baseline assessment included 
the collection of serum samples, MRI and the Expanded Dis-
ability Status Scale (EDSS). Serum samples were additionally 
collected after three, six, 12 and 24 months, MRI was per-
formed after nine, 12 and 24 months and EDSS was evaluated 
every six months. Patients with new T1 gadolinium-enhancing 
lesions and new T2 lesions had significantly higher serum NFL 
levels compared to patients without new changes in MRI. The 
presence of T1 gadolinium-enhancing lesions was correlated 
with serum NFL levels two months before and one month after 
biochemical measurements. The level of NFL decreased after 
inclusion of IFNB-1a treatment [28]. 
A third study was carried out on 86 patients with optic 
neuritis (ON) as the first manifestation of demyelination. The 
level of neurofilament light chain was examined in the cerebro-
spinal fluid. Patients were followed on average for 13.6 years, 
and 81.4% of patients were evaluated using MRI and EDSS 
scores. The remaining 18.6% of patients were questioned by 
telephone. During follow-up, 53.5% (46 patients) developed 
CDMS, and NFL predicted long-term disability by the multiple 
sclerosis severity scale [29].
The last study was performed on 75 patients with ra-
diologically isolated syndrome (RIS). The level of NFL was 
measured in cerebrospinal fluid. Neurofilament light chain 
was an independent risk factor for conversion to a CIS and 
MS. A high level of NFL was associated with a tendency to 
shorter conversion time to CIS, and much shorter to CDMS, 
which was more evident in RIS patients aged at least 37 years 
compared to younger patients [30].
In summary, the NFL level in the cerebrospinal fluid in 
patients with CIS and RRMS appears to be a strong potential 
prognostic factor in the assessment of disease activity [27, 31]. 
Serum NFL is a promising biochemical indicator for the 
effects of treatment in RRMS and an alternative to MRI in 
the assessment of subclinical disease activity [28, 32, 33]. 
Moreover, NFL turned out to be a predictor of long-term 
physical and cognitive disability after optic neuritis as the first 
demyelinating manifestation, and an independent risk factor 
for conversion to CIS and CDMS in patients with RIS [29, 30]. 
Chitinase 3-like 1(Human YKL-40, CHI3L1)  
and chitinase 3-like 2 (Human CHI3L2)
Chitinase 3-like 1 (Human YKL-40, CHI3L1) and chiti-
nase 3-like 2 (Human CHI3L2) are produced by neutrophils, 
astrocytes and macrophages as enzymatically inactive proteins 
which are involved in tissue remodelling and inflammation 
[34]. The levels of these substances increase in the cerebrospi-
nal fluid during various acute and chronic neuroinflammatory 
states, including MS [35]. 
One of the first studies to determine the usefulness of chiti-
nase 3-like 1 in the diagnosis of MS was a study performed on 
a group of 60 CIS patients, 30 of whom underwent conversion 
to CDMS, while the remaining 30 patients were stable CIS. 
Analysis of patient cerebrospinal fluid revealed a signi-
ficant correlation between the high level of CHI3L1 and the 
number of gadolinium-enhancing lesions as well as the num-
ber of T2 lesions in MRI at the beginning of the study, and was 
associated with a faster progression of disability and shorter 
conversion time to CDMS. The level of chitinase 3-like 1 was 
also higher among patients who underwent conversion to MS 
compared to those who remained stable CIS [36].
The above results have been confirmed in another longi-
tudinal cohort study carried out in 15 European MS centres. 
A total of 813 cerebrospinal fluid samples were collected from 
patients with a CIS. The CHI3L1 level was higher in patients 
who converted to CDMS compared to those who continued 
treatment as a CIS. A high level of CHI3L1 was also associated 
with a shorter conversion time to MS and faster development 
of disability [37].
Another study investigated the relationship between 
CHI3L1 levels and response to interferon-beta (IFNβ) and 
glatiramer acetate (GA) in patients with MS. The level of 
CHI3L1 in the cerebrospinal fluid of 117 patients with RRMS 
was measured, including 76 patients treated with IFNβ and 
41 treated with GA. The level of CHI3L1 was associated with 
the response to INFβ treatment, and was higher in the group 
of non-responders. Similar effects were not found among 
patients treated with GA. CHI3L1 may thus act as a response 
biomarker to INFβ in patients with RRMS [38].
Chitinase 3-like 1 can be used as a biomarker of disability 
development and as an effective marker to distinguish patients 
who will convert to CDMS from those who will remain as stable 
CIS in the future [36, 37]. CHI3L1 is also a potential biomarker 
for response to INFβ treatment in patients with RRMS [38].
On the other hand, the potential of chitinase 3-like 2 in the 
diagnosis of MS was examined in a prospective cohort study 
which included 73 patients with optic neuritis as the first de-
myelinating event, plus 26 age-matched healthy subjects. The 
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level of CHI3L2 was determined in the cerebrospinal fluid. 
The predictive capacity of CHI3L2 was compared to that of 
CHI3L1. The level of CHI3L2 was significantly elevated in pa-
tients with ON and was associated with the risk of developing 
MS. In addition, CHI3L2 was correlated with the risk of cog-
nitive impairment and MS development in patients after ON. 
CHI3L2 is a promising risk factor in patients with the 
first episode of demyelination. In multifactorial risk analysis 
of MS, CHI3L2 has been shown to be more effective than 
CHI3L1 [39].
Heat shock protein 70  and heat shock protein 90 
Heat shock proteins (HSPs) are molecular chaperones that 
play vital homeostatic roles in the central nervous system and 
whose distribution between different species is conservative. 
They can be divided into different groups depending on the 
molecular weight [40]. Heat shock protein 70 (HSP70) is loca-
lised in the cytosol, where it supports and protects cells against 
lethal stress-induced damage, as well as in the cell membrane 
and the intracellular space, where it plays an important role in 
the immune response [41, 42]. Elevated levels of HSP70 can 
have a beneficial effect on MS, protecting neurons and oli-
godendrocytes during an inflammatory process from death 
through apoptosis. However, the extracellular HSP70 may be 
responsible for induction of immunologic reaction [43, 44].
The first study was based on analysis of the HSPA1L gene 
polymorphism encoding the HSP70-hom protein among 
191 MS patients and 365 healthy subjects. There was a strong 
correlation between the polymorphism of the studied gene 
and the risk of MS development, as well as a significant rela-
tionship between the expression of the HSP70-hom protein 
and the severity of MS [45].
The purpose of further research was to determine the role 
of HSP70 as a potential biomarker in the differentiation of neu-
rodegenerative and inflammatory processes in MS. The serum 
of 94 patients with MS was examined, including 26 with CIS, 
40 with RRMS, 19 with secondary progressive MS (SPMS), and 
nine with primary progressive MS (PPMS). The control group 
consisted of 41 patients with non-inflammatory neurological 
diseases (NIND), 28 with other inflammatory neurological 
diseases (OIND), and 114 healthy donors (HD). The level 
of HSP70 in the serum of patients with MS was significantly 
higher than in HD, and significantly lower than in OINDs. 
Moreover, the analysis showed that the HSP70 level in patients 
with CIS or RRMS was significantly higher than in patients 
with PPMS or SPMS, which may be correlated with the stron-
gly expressed inflammatory process in the first group [46].
HSP70 is considered to be a useful biomarker to monitor 
inflammatory processes in MS in the future [45, 46]. Neverthe-
less, there is still no consensus as to whether HSP70 mediates 
the beneficial or negative effects of MS.
Heat shock protein 90 (HSP90) has similar properties 
to HSP70, differing only in molecular weight. It modulates 
inflammatory processes by producing anti-inflammatory 
cytokines and modulating the response with toll-like receptor 
2 and 4 (TLR2 and TLR4) [47]. 
One study evaluated the effect of HSP90 on steroid respon-
se in the treatment of relapses in MS patients. It was shown that 
the amount of HSP90 in the glucocorticoid receptor (GR) com-
plex was significantly higher in patients with steroid-resistant 
MS than in patients with steroid-sensitive MS. The mechanism 
of non-response to glucocorticoids may be associated with an 
increased presence of HSP90 in the cytoplasmic GR complex, 
which causes inhibition of GR translocation to the nucleus and 
reduction of its transcription [48]. 
Tubulin beta (TUBβ) 
Tubulins (TUBs) are heterodimeric proteins consisting 
of an alpha and a beta subunit and are major components of 
microtubules. The synthesis of class II tubulin isotype increases 
in development and regeneration of neurons. 
In one study, the level of cytoskeletal proteins, includ-
ing tubulin beta, in the cerebrospinal fluid of patients with 
MS and their correlation with clinical indicators of MS was 
assessed. The study was performed in 51 patients, including 
33 with MS and 18 with other neurological diseases (OND). 
Tubulin beta (TUBβ) level was significantly higher in MS 
patients than in OND patients [49]. Preliminary results show 
that TUBβ is a promising diagnostic factor in MS, but further 
analyses are needed.
Combined measurements of biochemical 
indicators and their impact on the diagnosis  
of MS
Recently, studies have been conducted to determine the 
effect of combined measurements of some of the above-
-discussed biomarkers levels in CSF and their role in the 
diagnosis of MS.
In a cross-sectional cohort study by Spanish researchers, 
the correlation between NFL and CHI3L1 levels in CSF in 
157 MS patients, including 99 patients with RRMS, 35 with 
SPMS, and 23 with PPMS, was investigated. After 50 months of 
observation, it was found that NFL and CHI3L1 levels in CSF 
were higher in patients with MS compared to patients in the 
disease-free control group. Increased levels of NFL in RRMS 
and SPMS patients were characteristic of clinical relapse, while 
high CHI3L1 levels were associated with progressive disease. 
NFL and CHI3L1 levels correlated with each other and with 
IgM-oligoclonal bands in RRMS patients. A formula of com-
bined measurements of biomarkers was useful in determining 
MS phenotypes and in predicting clinical progression. High 
NFL and low CHI3L1 levels occur more frequently in RRMS 
compared to SPMS and PPM. In turn, elevated levels of both 
biomarkers were ahead of diagnosis of clinical progression in 
patients with RRMS [50]. 
A second study tracked the diagnostic value of NFL and 
CHI3L1 levels in CSF in 177 newly diagnosed patients with 
CIS or RRMS. Patients were clinically followed for an average 
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Table 2. Usefulness of prognostic biomarkers in diagnosis of different types and stages of MS
CIS RIS ON RRMS CDMS S–R MS 
NFL + + + + + –
CHI3L1 + – – + + –
CHI3L2 – – + – – –
HSP70 + – – + – –
HSP90 – – – – – +
TUBβ – – – – + –
NFL — neurofilament light chain; CHI3L1 — chitinase 3-like 1; CHI3L2 — chitinase 3-like 2; HSP70 — heat shock protein 70; HSP90 — heat shock protein 90; TUBβ — tubulin beta; CIS — clinically isolated syn-
drome; RIS — radiologically isolated syndrome; ON — optic neuritis; RRMS — relapsing-remitting multiple sclerosis; CDMS — clinically defined multiple sclerosis; S-R MS — steroid-resistant multiple sclerosis; 
(+) useful in diagnostics; (–) not useful in diagnostics
of 5.7 years. Both NFL and CHI3L1 concentrations in CSF 
were associated with a higher risk of relapse during the first 
two years in one dimensional analyses, in contrast to mul-
tivariable analysis where only the NFL level was associated 
with relapse risk. No relationship was found between NFL or 
CHI3L1 concentrations and risk of conversion to SPMS or 
disability progression [51].
The research we have described shows that combined 
measurements of new biochemical indicators such as NFL 
and CHI3L1 levels in CSF may bring benefits in the diagnosis 
and prognosis of MS and may set a new direction for research 
using other biomarkers.
Clinical implications
MS is a disease that affects mainly young people and leads 
to their disability, which is why it is so important to diagnose 
it as early as possible. The insufficient accuracy of MRI in early 
MS diagnosis has led to a search for new predictors. Determi-
ning the OCBs level in the cerebrospinal fluid is included in 
the latest McDonald’s criteria for the diagnosis of MS. Recently, 
promising studies have been carried out on potential new 
biochemical markers in the blood serum and cerebrospinal 
fluid that may be useful in the diagnosis of different forms and 
stages of MS (Tab. 2). The first results of research on compo-
unds such as neurofilament light chain, chitinase 3-like 1 and 
2, heat shock proteins, tubulins, or combined measurements 
of some of these biomarkers, bring fresh hope for patients and 
for doctors seeking to diagnose MS. 
Future directions
Despite numerous studies on the use of biomarkers 
in the diagnosis of MS, more extensive research is needed 
to determine the clinical usefulness of these molecules. 
Identification of sensitive and specific biomarkers in CSF 
and blood serum of patients with CIS, the development of 
standardised diagnostic tests detecting these markers, and 
their use in everyday clinical practice, may result in earlier 
MS detection, faster implementation of treatment, and better 
therapeutic effects. 
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